Pancreatic Cancer Research

ResearcherSheng Jing HospitalActive in the last 2 years

Lingming Kong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7474-4844; OpenAlex author ID A5043213451. Sources: OpenAlex.

Their work

Papers
13 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2019: 2 papers · 2020: 5 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 13

  1. OCIAD2-IQGAP1 interaction promotes pancreatic cancer progression by suppressing oxidative stress and mitochondria-mediated apoptosis. First author DOI 10.1016/j.cellsig.2025.112217↗
  2. DPP4 suppresses pancreatic cancer growth by enhancing ferroptosis sensitivity through stabilization of ACSL4. First author DOI 10.1016/j.cellsig.2026.112446↗
  3. BUB1 Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Inhibiting Ferroptosis. Co-author DOI 10.3390/cancers16081540↗
  4. Identification of Prognosis-Related Molecular Subgroups and Construction of a Prognostic Prediction Model Using Immune-Related Genes in Pancreatic Cancer. First author DOI 10.1155/2022/7117014↗
  5. Identification of prognosis-related molecular subgroups based on DNA methylation in pancreatic cancer. First author DOI 10.1186/s13148-021-01090-w↗
  6. Identification of Novel Metabolism-Associated Subtypes for Pancreatic Cancer to Establish an Eighteen-Gene Risk Prediction Model. Co-author DOI 10.3389/fcell.2021.691161↗
  7. HOXB5 promotes proliferation, migration, and invasion of pancreatic cancer cell through the activation of the GSK3β/β-catenin pathway. Co-author DOI 10.1097/cad.0000000000000948↗
  8. Identification of dissociation factors in pancreatic Cancer using a mass spectrometry-based proteomic approach. First author DOI 10.1186/s12885-020-6522-3↗
  9. The miR-1224-5p/ELF3 Axis Regulates Malignant Behaviors of Pancreatic Cancer via PI3K/AKT/Notch Signaling Pathways. Co-author DOI 10.2147/ott.s248507↗
  10. Multi-omics analysis based on integrated genomics, epigenomics and transcriptomics in pancreatic cancer. Co-author DOI 10.2217/epi-2019-0374↗
  11. A Prognostic Prediction Model Developed Based on Four CpG Sites and Weighted Correlation Network Analysis Identified DNAJB1 as a Novel Biomarker for Pancreatic… Co-author DOI 10.3389/fonc.2020.01716↗
  12. Differential secretome of pancreatic cancer cells in serum-containing conditioned medium reveals CCT8 as a new biomarker of pancreatic cancer invasion and meta… First author DOI 10.1186/s12935-019-0980-1↗
  13. Identification of RE1-Silencing Transcription Factor as a Promoter of Metastasis in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2019.00291↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaodong Tan · 9 shared papers, 2019–2022 · strength 1.20
  2. Peng Liu · 8 shared papers, 2019–2022 · strength 1.10
  3. Gang Chen · 3 shared papers, 2024–2026 · strength 0.91
  4. Zhenyan Pan · 2 shared papers, 2024–2026 · strength 0.55
  5. Yang Gao · 3 shared papers, 2019–2020 · strength 0.38
  6. Keke Liang · 3 shared papers, 2020 · strength 0.38
  7. Xiang Zhou · 1 shared paper, 2026 · strength 0.36
  8. Haoyi Jin · 3 shared papers, 2019–2020 · strength 0.34
  9. Xiang Fei · 2 shared papers, 2020–2022 · strength 0.33
  10. Xiang Zhou · 1 shared paper, 2024 · strength 0.28
  11. Wei‐Ming Wang · 1 shared paper, 2024 · strength 0.28
  12. Xiang Fei · 2 shared papers, 2020–2021 · strength 0.28
  13. Qiandong Zhu · 1 shared paper, 2026 · strength 0.27
  14. Bing Song · 2 shared papers, 2019–2020 · strength 0.24
  15. Yunhao Wu · 2 shared papers, 2019–2020 · strength 0.24
  16. Xiaoli Yin · 1 shared paper, 2021 · strength 0.22
  17. Peng Liu · 1 shared paper, 2021 · strength 0.16
  18. Yang Gao · 1 shared paper, 2021 · strength 0.16
  19. Defeng Sun · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.